-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
SARS-CoV-2-nsp13-IN-5
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/912799-11-2.gif)
| Category | SARS-CoV |
| CAS | 912799-11-2 |
| Description | SARS-CoV-2 nsp13-IN-5 (compound C6) is a potent SARS-CoV-2 nsp13 inhibitor with IC50 values of 50 and 55 μM for ssDNA+ ATPase and ssDNA- ATPase. SARS-CoV-2 nsp13-IN-5 can be used for researching anti-COVID-19. |
Product Information
| Synonyms | SARS-CoV-2 nsp13-IN-5|CHEMBL1322214|HMS1817K12|ZINC8593126|NCGC00106011-01|HY-150626|CS-0534898|C241-1381|4-[1-{2-[(2,6-dimethylphenyl)amino]-2-oxoethyl}-2,4-dioxo-1,4-dihydrothieno[3,2-d]pyrimidin-3(2H)-yl]-N-(4-methylbenzyl)butanamide |
| Molecular Weight | 518.63 |
| Molecular Formula | C28H30N4O4S |
| Canonical SMILES | CC1=CC=C(C=C1)CNC(=O)CCCN2C(=O)C3=C(C=CS3)N(C2=O)CC(=O)NC4=C(C=CC=C4C)C |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 836 |
| Exact Mass | 518.19877662 |
| Target | IC50: 50 μM (ssDNA+ ATPase), 55 μM (ssDNA- ATPase) |
| XLogP3-AA | 3.9 |
